Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial
The addition of camrelizumab and rivoceranib to TACE showed statistically significant improvement in PFS for patients with unresectable HCC, with a manageable safety profile. Follow-up for further overall survival analysis is ongoing.
Authors
- Weizhu Yang (ORCID: https://orcid.org/0000-0001-8470-1709)
- Haidong Zhu (ORCID: https://orcid.org/0000-0003-4000-3081)
- Yusheng Song (ORCID: https://orcid.org/0000-0002-9084-2804)
- Weiguo Xu (ORCID: https://orcid.org/0000-0002-0146-8532)
- Wenheng Zheng (ORCID: https://orcid.org/0009-0006-1212-2824)
- Haibo Shao (ORCID: https://orcid.org/0000-0002-0998-3475)
- Ni Guan
- Yuxuan Wang (ORCID: https://orcid.org/0000-0002-1649-6974)
- Yuliang Li (ORCID: https://orcid.org/0000-0002-0634-7035)
- Longzhen Piao (ORCID: https://orcid.org/0000-0002-2221-0020)
- Jianbo Zhao (ORCID: https://orcid.org/0000-0003-4330-0938)
- Shanzhi Gu (ORCID: https://orcid.org/0000-0002-6603-7792)
- Weifu Lv
- Hailan Lin
- Zhi-guo Hou
- Zhi-Cheng JIN
- G. Teng
- S. Wang
- W. Fan
- Jiansong Ji (ORCID: https://orcid.org/0000-0003-1314-396X)
- Y. J. Zeng
- Xu-Ya Zhao
- Zhe-Wei Zhang
- Ying Sun
- Jin-He Guo
- Hong-Tao Cheng
- Jian Lu
- Qi Zhang
- Ming Huang
- Chang Zhao
- Hao Xu
Institutions
- Qingdao University (CN)
- University of Science and Technology of China (CN)
- Fujian Medical University (CN)
- Sun Yat-sen University (CN)
- Jinan University (CN)
- Xuzhou Medical College (CN)
- Yanbian University (CN)
- Kunming Medical University (CN)
- Lishui University (CN)
- Zhengzhou University (CN)
- Southeast University (BD)
- Ganzhou People's Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Guizhou Cancer Hospital (CN)
- Second Hospital of Shandong University (CN)
- Zhuhai People's Hospital (CN)
- Zhongda Hospital Southeast University (CN)
- Hunan Cancer Hospital (CN)
- Mengchao Hepatobiliary Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Jiangsu Hengrui Medicine (China) (CN)
- Fujian Provincial Cancer Hospital (CN)
- Tumor Hospital of Guangxi Medical University (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Union Hospital (CN)
- Hangzhou Cancer Hospital (CN)
- Southern Medical University (CN)
- Zhejiang University (CN)
- Southeast University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1200/jco-25-01796
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00